Whatever brought you here — trauma, addiction, a heaviness that won't lift, an alarm that won't quiet — it has a shape, and it has a way out. This is a place to understand it honestly.
Opioid, alcohol and stimulant dependence, treatment-resistant depression and anxiety, PTSD and trauma, traumatic brain injury, chronic pain entangled with opioids, and distress in serious illness — each with a different treatment fit and a different evidence level, which is why we start from the condition, not the medicine.
When trauma lives in the body, it keeps firing long after the danger has passed. Talk therapy and medication reach only so far — for many, psychedelic-assisted therapy finally loosens what's been locked in place for years.
Addiction physically rewires the brain's reward system, and standard care relapses more often than it works. Ibogaine can interrupt the withdrawal-and-relapse cycle in a single supervised experience — a genuine chemical reset to build on.
One of the most widespread conditions in the world — and the standard first answer, an SSRI, works for fewer people than most assume. For treatment-resistant depression, newer options can lift the weight in days, not weeks.
Chronic anxiety keeps the nervous system braced for impact, and willpower rarely turns it off. The go-to answer — a benzodiazepine — calms the moment but creates dependence. Psychedelic-assisted therapy can quiet the alarm at its source.
Pick what fits closest — each opens a plain-language picture of the experience, then traces it through the root map below.
A symptom is rarely just a symptom — it cascades outward into the rest of a life. Trace any symptom to see where it leads, or any life consequence to see what feeds it.
Most psychedelic-assisted therapies can benefit these conditions in some way — an advisor helps find what genuinely fits. See all treatments →
An honest conversation about what you're experiencing and the paths worth considering — from people who've been through these treatments themselves.
Condition guides, the ibogaine-specific pages for each dependence, and the pages written for particular groups.
Opioid dependence for ibogaine (observational, 12-month follow-up data), depression for psilocybin (randomised trials), PTSD for MDMA (phase 3) and for ibogaine in veterans (open-label).
Often they co-occur — trauma and dependence, pain and opioids — and a single well-screened program can address both; the aftercare plan has to cover both too.
Cardiac conditions and certain medications for ibogaine; some psychiatric conditions for classic psychedelics. Screening decides, and we tell you honestly.
Call or text (866) 435-7057 or request a consultation.
